title: Cidofovir in pediatric solid organ transplant recipients: University of Nebraska experience.
abstract: BACKGROUND
  Clinical experience with cidofovir in pediatric solid organ transplantation is limited. We assessed the effect of cidofovir use on renal function in pediatric solid organ transplant recipients.
  
  
  METHODS
  Wilcoxon signed-rank tests were used to determine if changes in renal function were significant, Wilcoxon rank-sum tests to test the association between changes in glomerular filtration rate and potential confounding factors, and MacNemar tests to compare the proportions of patients at different time points.
  
  
  RESULTS
  We included 25 patients with a mean age of 4.2 years (SD 4.6). More patients were receiving renal replacement therapy while being treated with cidofovir compared with baseline (24% vs. 4%; P = 0.03). For patients not receiving renal replacement therapy, there was no evidence of a significant median change in glomerular filtration rate from baseline to 1 month after cidofovir treatment (P = 0.32) or to the end of cidofovir treatment (P = 0.23) or in creatinine from baseline to the end of cidofovir therapy (P = 0.2). There was a marginal decreased median change in creatinine from baseline to 1 month after cidofovir treatment (P = 0.06). Fewer patients had proteinuria (72.2% vs. 27.8%; P = 0.02) and hematuria (22.2% vs. 0%) after cidofovir treatment.
  
  
  CONCLUSIONS
  In our pediatric transplant cohort, cidofovir did not significantly change renal function reflected by creatinine, glomerular filtration rate, hematuria or proteinuria, but a significant number of patients required renal replacement therapy because of fluid overload.
authors.affiliation: From the *Transplant Infectious Diseases Program; †Transplant Surgery Division; ‡Department of Biostatistics, University of Nebraska Medical Center; §Department of Pharmaceutical and Nutrition Care, Nebraska Medical Center Omaha, NE; and ¶Nephrology Division, University of Nebraska Medical Center, Omaha, NE.
authors.forename: Diana F
authors.initials: DF
authors.lastname: Florescu
authors.forename: Heather E
authors.initials: HE
authors.lastname: Chambers
authors.forename: Fang
authors.initials: F
authors.lastname: Qiu
authors.forename: Megan A
authors.initials: MA
authors.lastname: Keck
authors.forename: David F
authors.initials: DF
authors.lastname: Mercer
authors.forename: Michael C
authors.initials: MC
authors.lastname: Morris
authors.forename: Marius C
authors.initials: MC
authors.lastname: Florescu
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D000077404:Cidofovir; D015331:Cohort Studies; D003404:Creatinine / Q000097:blood; D003596:Cytosine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects*; D006417:Hematuria / Q000139:chemically induced; D006785:Hospitals, University; D006801:Humans; D007223:Infant; D007668:Kidney / Q000187:drug effects* / Q000502:physiology*; D008297:Male; D009329:Nebraska; D063065:Organophosphonates / Q000008:administration & dosage* / Q000009:adverse effects*; D011507:Proteinuria / Q000139:chemically induced; D012189:Retrospective Studies; D019737:Transplants
chemical_list: D000998:Antiviral Agents; D063065:Organophosphonates; D003596:Cytosine; D003404:Creatinine; D000077404:Cidofovir